Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"

被引：8

|

作者：

Webster, Christopher J. ^{[1
]}

Woollett, Gillian R. ^{[2
]}

机构：

[1] BioApprovals, Acton, MA USA

[2] Avalere Hlth Inc, FDA Strategy & Regulatory Policy, Washington, DC 20036 USA

来源：

BIODRUGS | 2018年 / 32卷 / 05期

关键词：

D O I：

10.1007/s40259-018-0297-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：519 / 521

页数：3

相关论文

共 50 条

[1] Comment on "The End of Phase 3 Clinical Trials in Biosimilars Development?"
Niazi, Sarfaraz K.
BIODRUGS, 2019, 33 (01) : 121 - 123
[2] Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Christopher J. Webster
Gillian R. Woollett
BioDrugs, 2018, 32 : 519 - 521
[3] Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Sarfaraz K. Niazi
BioDrugs, 2019, 33 : 121 - 123
[4] The End of Phase 3 Clinical Trials in Biosimilars Development?
Francois-Xavier Frapaise
BioDrugs, 2018, 32 : 319 - 324
[5] The End of Phase 3 Clinical Trials in Biosimilars Development?
Frapaise, Francois-Xavier
BIODRUGS, 2018, 32 (04) : 319 - 324
[6] Author's Reply to Webster and Woollett: "The End of Phase 3 Clinical Trials in Biosimilars Development?"
Frapaise, Francois-Xavier
BIODRUGS, 2018, 32 (05) : 523 - 523
[7] Author’s Reply to Webster and Woollett: “The End of Phase 3 Clinical Trials in Biosimilars Development?”
Francois-Xavier Frapaise
BioDrugs, 2018, 32 : 523 - 523
[8] Biosimilars in rheumatology. Development and results of clinical trials
Alten, R.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2015, 74 (08): : 682 - +
[9] Developing Clinical Trials for Biosimilars
Bui, Lynne A.
Taylor, Carrie
SEMINARS IN ONCOLOGY, 2014, 41 (01) : S15 - S25
[10] Clinical trials for trastuzumab biosimilars
Derbyshire, Michelle
GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2020, 9 (02): : 84 - 89

← 1 2 3 4 5 →